This fall, the 'Korea Blockchain Week (KBW) 2026' will take place in Seoul, bringing together policymakers and key figures from traditional finance and the AI sector from around the world. The event organizer, FactBlock, has announced the third speaker lineup for the 'KBW 2026 Main Conference,' which will be held from September 30 to October 1. The conference will reflect recent industry trends, including the introduction of digital asset regulations, market entry of traditional finance, and the integration of AI technologies. Notable participants include Bermuda's Prime Minister David Burt, former CFTC Chairperson Caroline Pham, and Chris Land, the Chief Policy Advisor of the U.S. Senate's Digital Assets Subcommittee. The blockchain and AI fusion session will feature Michael Heinrich, co-founder of 0G, and Jun Morita, General Manager of Purplecity AI for the Asia-Pacific region. Institutional investors and representatives from digital asset companies will include Chetan Kakanis from Franklin Templeton and Ella Zhang from YZi Labs. OKX founder Star Xu and World Liberty Financial CEO Jack Witkoff will also present. Park Wi-ik, CEO of FactBlock, stated that KBW 2026 will be a platform for global leaders to explore the direction of the digital asset market.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.


Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.















Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.













Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.